IV Sodium Ferric Gluconate Complex in Patients Hospitalized Due to Acute Decompensated Heart Failure and Iron Deficiency
Background: Patients suffering from heart failure (HF) and iron deficiency (ID) have worse outcomes. Treatment with intra-venous (IV) ferric carboxymaltose has been shown to reduce HF rehospitalizations and to improve functional capacity and symptoms in patients with HF and reduced ejection fraction...
Main Authors: | Itay Borreda MD, Robert Zukermann MD, Danny Epstein MD, Erez Marcusohn MD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-01-01
|
Series: | Journal of Cardiovascular Pharmacology and Therapeutics |
Online Access: | https://doi.org/10.1177/10742484211055639 |
Similar Items
-
Left Ventricular Systolic Dysfunction Due to Atrial Fibrillation: Clinical and Echocardiographic Predictors
by: Erez Marcusohn, et al.
Published: (2021-11-01) -
Ferric Carboxymaltose in Patients with Acute Decompensated Heart Failure and Iron Deficiency: A Real-Life Study
by: Federico Capone, et al.
Published: (2023-08-01) -
Ferric sodium edetate therapy in children with iron deficiency anemia
by: Christie Moningkey, et al.
Published: (2015-04-01) -
The Switch from Ferric Gluconate to Ferric Carboxymaltose in Hemodialysis Patients Acts on Iron Metabolism, Erythropoietin, and Costs: A Retrospective Analysis
by: Antonio Lacquaniti, et al.
Published: (2023-06-01) -
IV Ferric Carboxymaltose Vs Oral Iron in the Treatment of Post-partum Iron Deficiency Anaemia
by: Sree Chandana Damineni, et al.
Published: (2016-11-01)